Australian health regulators quietly gave Epidiolex, a cannabidiol medication, orphan designation and priority review status in late 2019.
The designations allow the Therapeutic Goods Administration to wave application and evaluation fees, as well as expediting its assessment of the application to list Epidiolex in the ARTG, the Department of Health disclosed in a recent public submission to a Senate committee.
Australia expedites review of medical cannabis product Epidiolex
